Abivax SA (id:10801 ABVX)
8.04 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/28/2024 1:46:36 AM)
Exchange closed, opens in 7 hours 13 minutes
0.37 EUR (0.37%)
-3.02 EUR (-3.02%)
-15.63 EUR (-15.63%)
-35.89 EUR (-35.89%)
-14.92 EUR (-14.92%)
-30.81 EUR (-30.81%)
-63.95 EUR (-63.95%)
About Abivax SA
Market Capitalization 509.55M
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
| Headquarters (address) |
7-11 boulevard Haussmann Paris 75009 France |
| Phone | 33 1 53 83 09 63 |
| Website | https://www.abivax.com |
| Employees | 62 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ABVX |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 7.59 - 15.42 |
| Market Capitalization | 509.55M |
| P/E trailing | -2.34 |
| P/E forward | -5.33 |
| Price/Sale | 56.42 |
| Price/Book | 3.90 |
| Beta | 1.42 |
| EPS | -3.43 |
| EPS France (ID:70, base:331) | 3.06 |